మా గ్రూప్ ప్రతి సంవత్సరం USA, యూరప్ & ఆసియా అంతటా 3000+ గ్లోబల్ కాన్ఫరెన్స్ ఈవెంట్లను నిర్వహిస్తుంది మరియు 1000 కంటే ఎక్కువ సైంటిఫిక్ సొసైటీల మద్దతుతో 700+ ఓపెన్ యాక్సెస్ జర్నల్లను ప్రచురిస్తుంది , ఇందులో 50000 మంది ప్రముఖ వ్యక్తులు, ప్రఖ్యాత శాస్త్రవేత్తలు ఎడిటోరియల్ బోర్డ్ సభ్యులుగా ఉన్నారు.
ఎక్కువ మంది పాఠకులు మరియు అనులేఖనాలను పొందే ఓపెన్ యాక్సెస్ జర్నల్స్
700 జర్నల్స్ మరియు 15,000,000 రీడర్లు ప్రతి జర్నల్ 25,000+ రీడర్లను పొందుతున్నారు
Geeta Shroff and Petra Hopf-Seidel
Parkinson’s disease (PD), a progressive disorder of the central nervous system, affects every 1 in 100 persons, aged around 70 in Europe. PD is characterized by abnormalities affecting both the motor system and the non-motor systems that include tremor, gait disorder, bradykinesia, depression, cognitive impairments, dysautonomia and sleep disturbances. Both surgical and drug treatments are available for the treatment of PD, but none has been able to halt the progression of the degenerative disease. We present the case of 65-year old male patient with PD who was treated with human embryonic stem cells (hESCs). The patient showed significant improvement in his health following the treatment; such as reduction in tremors, bradykinesia, muscle rigidity, pain and stiffness in the neck, shoulder and low back and improvement in the range of movements of the neck. The patient was able to balance himself while walking, had reduction in numbness in his left hand and both of his legs. He was able to speak louder and had improved writing skills. No adverse event or teratoma formation was observed. hESC therapy in our study showed beneficial effects in the patient with PD, but future clinical trials are needed to gather more evidence to support our findings.